Vitrolife Signs Collaboration Agreement with Cellartis
KUNGSBACKA, Sweden--Vitrolife (STO:VITR) has signed a collaboration agreement with Cellartis AB, Gteborg, regarding the development of new products for cultivation, handling and differentiation of stem cells. The new agreement extends the present collaboration between the companies. The agreement is spanning over 2 years. Its financial details will not be made public.
Kungsbacka June 7, 2007
Magnus Nilsson CEO
Information Cellartis:
Cellartis AB is focused on research, development and production of human embryonic stem cells and differential cells derived for stem cells. For more information www.cellartis.com
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media) and advanced one-time instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.
Vitrolife today has approximately 120 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.
This information was brought to you by Cision http://newsroom.cision.com
Contacts
Vitrolife
Magnus Nilsson, CEO
Tel. +46 31 721 80 00 / +46 708 22 80 61
or
Anna Ahlberg, CFO
Tel. +46 31 721 80 13 / +46 708 22 80 13
Kungsbacka June 7, 2007
Magnus Nilsson CEO
Information Cellartis:
Cellartis AB is focused on research, development and production of human embryonic stem cells and differential cells derived for stem cells. For more information www.cellartis.com
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media) and advanced one-time instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.
Vitrolife today has approximately 120 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.
This information was brought to you by Cision http://newsroom.cision.com
Contacts
Vitrolife
Magnus Nilsson, CEO
Tel. +46 31 721 80 00 / +46 708 22 80 61
or
Anna Ahlberg, CFO
Tel. +46 31 721 80 13 / +46 708 22 80 13
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.